PointellisTM provides the information exchange infrastructure to help enable safe and accurate delivery of cell and gene therapies (CGT) to patients at the right time and place, every time.  

What EY can do for you

EY PointellisTM, is a solution that reimagines the biopharma supply chain, and its processes and tools, to help provide patients with groundbreaking cell and gene therapies, in the timeliest way possible.

How EY teams can help the cell and gene therapy community

The EY teams are working with people and organizations in health, life sciences, logistics and other sectors to continue to develop Pointellis™ — an information exchange platform that collects and shares data in a way that benefits all participants in the CGT ecosystem, and in an environment they can all trust.

The challenges of scaling emerging therapies

Breakthrough discoveries in cell and gene therapies offer new hope to people with a range of diseases. But how do we make them available to every patient and family that can benefit?

Cell and gene therapies are changing people’s lives, but the way they’re delivered today, through the existing CGT ecosystem, won’t scale. The only way to make cell and gene therapies a reality at scale is to create an ecosystem of different organizations working together and sharing data and information they all trust.

No single player, regardless of funding, can do this on its own.

It will require a total transformation in the way we exchange data with players across the CGT value chain, in unprecedented ways.

This means connecting every individual and organization with a stake in the patient’s care to a platform of securely shared data and information — from the nurse taking a tissue sample, to the truck driver who delivers it to a lab and the patient who is waiting for their finished treatment, to the health care provider that administers it, the payer that funds it and the regulator that oversees it.

They all need to be on the same page, working together, with data they can trust.

Why EY?

The EY organization is already a part of the ecosystem needed to make it happen. The EY professionals are working with leaders in health, life sciences, logistics and other sectors to continue to develop Pointellis™. This information platform will be critical to the widespread adoption of these breakthrough medicines.

An ecosystem with Pointellis™ at its core will have the capabilities, services and analytics needed to revolutionize patient outcomes, at scale.

Robust, compliant and secure information provided through Pointellis™ will allow each value chain participant to focus on executing their important roles in the treatment journey:

  • Patients will better understand where their treatment is through their own patient-support application.
  • Physicians will have up-to-date information of the patient’s therapy status in order to make timely care decisions.
  • Case workers can track and trace patient tissues, blood samples and finished therapies all the way through the treatment process.
  • Manufacturers are able to optimize their manufacturing capacity so as many patients as possible can receive treatment.

At EY, we want to help make cell and gene therapies available to every person and family that can benefit. By doing what EY teams do best — harnessing the transforming power of data, technology and stewardship of information — we can allow everyone else in the ecosystem to focus on what they do best, from developing new science, to delivering outstanding logistics, to giving patients the  best medical care possible.

This is how we’re building a better working world.

Safe, accurate delivery of individualized cell and gene therapies

EY launches PointellisTM to enable the delivery of individualized cell and gene therapies to patients as personal as the therapies themselves.


Discover more

Contact us

Like what you’ve seen? Get in touch to learn more.